George Simeon bought CRSP
July 16, 2025 · Form 4 insider transaction
George Simeon bought 22,319 shares of CRISPR Therapeutics AG at $52.03 per share, a transaction worth $1.16M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
The Reporting Person is the sole managing member of SR One Capital Management, which is the sole general partner of SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I"). SR One Opportunities Partners I is the sole general partner of SR One Capital Opportunities Fund I, LP ("SR One Opportunities Fund I"), which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 or otherwise of such portion of the securities held by SR One Opportunities Fund I in which the Reporting Person has no pecuniary interest.